GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » Debt-to-EBITDA

TalkMed Group (SGX:5G3) Debt-to-EBITDA : 0.11 (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

TalkMed Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$4.99 Mil. TalkMed Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was S$3.73 Mil. TalkMed Group's annualized EBITDA for the quarter that ended in Dec. 2024 was S$80.61 Mil. TalkMed Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for TalkMed Group's Debt-to-EBITDA or its related term are showing as below:

SGX:5G3' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03   Med: 0.19   Max: 0.35
Current: 0.17

During the past 13 years, the highest Debt-to-EBITDA Ratio of TalkMed Group was 0.35. The lowest was 0.03. And the median was 0.19.

SGX:5G3's Debt-to-EBITDA is ranked better than
90.35% of 456 companies
in the Healthcare Providers & Services industry
Industry Median: 2.38 vs SGX:5G3: 0.17

TalkMed Group Debt-to-EBITDA Historical Data

The historical data trend for TalkMed Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TalkMed Group Debt-to-EBITDA Chart

TalkMed Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.35 0.30 0.18 0.22 0.17

TalkMed Group Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.15 0.20 0.20 0.33 0.11

Competitive Comparison of TalkMed Group's Debt-to-EBITDA

For the Medical Care Facilities subindustry, TalkMed Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TalkMed Group's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TalkMed Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where TalkMed Group's Debt-to-EBITDA falls into.


;
;

TalkMed Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

TalkMed Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.986 + 3.725) / 52.882
=0.16

TalkMed Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.986 + 3.725) / 80.608
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.


TalkMed Group  (SGX:5G3) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


TalkMed Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of TalkMed Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


TalkMed Group Business Description

Traded in Other Exchanges
N/A
Address
3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510
TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into two reportable operating segments, Oncology Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, China and Hong Kong, Australia, Vietnam and others of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.

TalkMed Group Headlines

No Headlines